Fifty 410 vs MEDVi
$133/mo against $399/mo for tirzepatide. Which is worth it, and for whom.
Updated 2026-09-18
Both sell tirzepatide. Fifty 410 costs $133 a month and MEDVi costs $399, a difference of $266 a month or about $3,192 a year. The desk reads it as follows.
Fifty 410 is prepaid blocks with no subscription. MEDVi is tablet and injection choice. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.
Advert against bill. Fifty 410 advertises $133 and bills $133; MEDVi advertises $399 and bills $399. Both gaps are the same size, so the advertised comparison happens to hold.
Side by side
| Fifty 410 | MEDVi | |
|---|---|---|
| Advertised | $133 | $399 |
| Billed | $133 | $399 |
| Gap | none | none |
| Per year, billed | $1,596 | $4,788 |
Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.
The split
2 differences on the record. The others match.
| Fifty 410 | MEDVi | |
|---|---|---|
| Month-to-month without prepaying a block | No | Yes |
| Offers an oral or sublingual option | No | Yes |
What each puts on the record: Fifty 410
- Provider consultation and free 1-2 day shipping included in the price.
- States it is a telehealth platform that does not compound or distribute medication itself, and that preparations come from FDA-registered 503A pharmacies.
Where it wins: Genuinely no subscription — you buy a block and nothing recurs. Watch for: The $133 is the starter protocol. Moving to the high-dose protocol takes it to $183/month, and both are prepaid three-month commitments.
What each puts on the record: MEDVi
Where it wins: Injection pricing is consistent between the first month and renewals. Watch for: You have to complete intake before seeing tablet pricing. Injection pricing is published at $399.
In each one’s favour
Fifty 410.
- Genuinely no subscription — you buy a block and nothing recurs.
- Among the lowest tirzepatide rates verified.
MEDVi.
- Injection pricing is consistent between the first month and renewals.
- Tablet option for people who will not inject.
Fifty 410 scores higher overall at 4.2 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.
The desk’s call
The board says Fifty 410. What the board cannot say is whether the advertised figures you were shown elsewhere match these — check the gap row, because a listing that advertises low and bills high will beat an honest one in any comparison built on advertised prices.
The verdict
On the board, Fifty 410 at $133 a month is the more defensible choice on arithmetic alone. MEDVi earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: Fifty 410 and MEDVi.
How they sit against everyone else
| Programme | Advertised | Billed | Gap | Vs board floor |
|---|---|---|---|---|
| Coreage Rx | $149 | $199 | +$50 | +$74/mo |
| Trimi | $125 | $125 | none | — |
| Ozari Health | $125 | $125 | none | — |
| Fifty 410 | $133 | $133 | none | +$8/mo |
More from the desk
- Fifty 410 tirzepatide review
Advertised at $133 and billed at $133 — no gap. Position 4 of 18 on our board.
- MEDVi tirzepatide review
Advertised at $399 and billed at $399 — no gap. Position 14 of 18 on our board.
- How to spot a bad seller
The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.
- The twelve-month cost
Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.
- Cheapest right now
Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure
